These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22380010)

  • 41. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery?
    Fahr A; van Hoogevest P; Kuntsche J; Leigh ML
    J Liposome Res; 2006; 16(3):281-301. PubMed ID: 16952882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.
    Trevaskis NL; Charman WN; Porter CJ
    Adv Drug Deliv Rev; 2008 Mar; 60(6):702-16. PubMed ID: 18155316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of lymphatic transport in enhancing oral protein and peptide drug delivery.
    Wasan KM
    Drug Dev Ind Pharm; 2002 Oct; 28(9):1047-58. PubMed ID: 12455465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral Absorption Promoters: Opportunities, Issues, and Challenges.
    Yewale C; Patil S; Kolate A; Kore G; Misra A
    Crit Rev Ther Drug Carrier Syst; 2015; 32(5):363-87. PubMed ID: 26559432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Armamentarium of nanoscaled lipid drug delivery systems customized for oral administration: In silico docking patronage, absorption phenomenon, preclinical status, clinical status and future prospects.
    Baldi A; Chaudhary M; Sethi S; Abhiav ; Chandra R; Madan J
    Colloids Surf B Biointerfaces; 2018 Oct; 170():637-647. PubMed ID: 29986259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
    He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
    Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Impact of intestinal metabolism on drug development].
    Mizuma T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):142-5. PubMed ID: 19749486
    [No Abstract]   [Full Text] [Related]  

  • 49. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes.
    Silva AC; Santos D; Ferreira D; Lopes CM
    Curr Med Chem; 2012; 19(26):4495-510. PubMed ID: 22834821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Palatal mucosa as a route for systemic drug delivery: A review.
    Shakya P; Madhav NV; Shakya AK; Singh K
    J Control Release; 2011 Apr; 151(1):2-9. PubMed ID: 21059376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of the transmucosal drug delivery.
    Manganaro AM
    Mil Med; 1997 Jan; 162(1):27-30. PubMed ID: 9002699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers.
    Rabanel JM; Aoun V; Elkin I; Mokhtar M; Hildgen P
    Curr Med Chem; 2012; 19(19):3070-102. PubMed ID: 22612696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting membrane transporters and receptors as a mean to optimize orally delivered biotechnological based drugs through nanoparticle delivery systems.
    Pereira C; Araújo F; Granja PL; Santos HA; Sarmento B
    Curr Pharm Biotechnol; 2014; 15(7):650-8. PubMed ID: 25219864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Permeation enhancer strategies in transdermal drug delivery.
    Marwah H; Garg T; Goyal AK; Rath G
    Drug Deliv; 2016; 23(2):564-78. PubMed ID: 25006687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling.
    Alqahtani S; Bukhari I; Albassam A; Alenazi M
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):625-634. PubMed ID: 29806951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ontogeny of oral drug absorption processes in children.
    Mooij MG; de Koning BA; Huijsman ML; de Wildt SN
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1293-303. PubMed ID: 22686526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Versatile Oral Insulin Delivery Nanosystems: From Materials to Nanostructures.
    Wang M; Wang C; Ren S; Pan J; Wang Y; Shen Y; Zeng Z; Cui H; Zhao X
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs.
    Karwal R; Garg T; Rath G; Markandeywar TS
    Crit Rev Ther Drug Carrier Syst; 2016; 33(1):1-39. PubMed ID: 27279337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of semi-synthetic biopolymer complexes: modified polysaccharide nano-carriers for enhancement of oral drug bioavailability.
    Sithole MN; Choonara YE; du Toit LC; Kumar P; Pillay V
    Pharm Dev Technol; 2017 Mar; 22(2):283-295. PubMed ID: 27470222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.